Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kristell Lebozec

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
New Biotechnology|April 25, 2018
Quality and cost assessment of a recombinant antibody fragment produced from mammalian, yeast and prokaryotic host cells: A case study prior to pharmaceutical developmentKristell Lebozec, Martine Jandrot-Perrus, Gilles Avenard, et al.
Mabs|June 10, 2017
Design, development and characterization of ACT017, a humanized Fab that blocks platelet's glycoprotein VI function without causing bleeding risksKristell Lebozec, Martine Jandrot-Perrus, Gilles Avenard, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|April 19, 2011
Anionic polymers for decreased toxicity and enhanced in vivo delivery of siRNA complexed with cationic liposomesAnne Schlegel, Céline Largeau, Pascal Bigey, et al.
Journal of Clinical Pharmacology|June 6, 2020
Population Pharmacokinetic/Pharmacodynamic Modeling of Glenzocimab (ACT017) a Glycoprotein VI Inhibitor of Collagen-Induced Platelet AggregationLionel Renaud, Kristell Lebozec, Christine Voors-Pette, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|October 12, 2013
Crucial role for endoplasmic reticulum stress during megakaryocyte maturationJose J Lopez, Alberta Palazzo, Chiraz Chaabane, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|April 25, 2019
Safety and Tolerability, Pharmacokinetics, and Pharmacodynamics of ACT017, an Antiplatelet GPVI (Glycoprotein VI) FabChristine Voors-Pette, Kristell Lebozec, Peter Dogterom, et al.
Blood Advances|November 14, 2022
Targeting platelet GPVI with glenzocimab: a novel mechanism for inhibitionPhilippe Billiald, Alexandre Slater, Martin Welin, et al.
Nature Medicine|May 5, 2015
Irf5 deficiency in macrophages promotes beneficial adipose tissue expansion and insulin sensitivity during obesityElise Dalmas, Amine Toubal, Fawaz Alzaid, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
New Biotechnology|April 25, 2018
Quality and cost assessment of a recombinant antibody fragment produced from mammalian, yeast and prokaryotic host cells: A case study prior to pharmaceutical developmentKristell Lebozec, Martine Jandrot-Perrus, Gilles Avenard, et al.
Mabs|June 10, 2017
Design, development and characterization of ACT017, a humanized Fab that blocks platelet's glycoprotein VI function without causing bleeding risksKristell Lebozec, Martine Jandrot-Perrus, Gilles Avenard, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|April 19, 2011
Anionic polymers for decreased toxicity and enhanced in vivo delivery of siRNA complexed with cationic liposomesAnne Schlegel, Céline Largeau, Pascal Bigey, et al.
Journal of Clinical Pharmacology|June 6, 2020
Population Pharmacokinetic/Pharmacodynamic Modeling of Glenzocimab (ACT017) a Glycoprotein VI Inhibitor of Collagen-Induced Platelet AggregationLionel Renaud, Kristell Lebozec, Christine Voors-Pette, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|October 12, 2013
Crucial role for endoplasmic reticulum stress during megakaryocyte maturationJose J Lopez, Alberta Palazzo, Chiraz Chaabane, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|April 25, 2019
Safety and Tolerability, Pharmacokinetics, and Pharmacodynamics of ACT017, an Antiplatelet GPVI (Glycoprotein VI) FabChristine Voors-Pette, Kristell Lebozec, Peter Dogterom, et al.
Blood Advances|November 14, 2022
Targeting platelet GPVI with glenzocimab: a novel mechanism for inhibitionPhilippe Billiald, Alexandre Slater, Martin Welin, et al.
Nature Medicine|May 5, 2015
Irf5 deficiency in macrophages promotes beneficial adipose tissue expansion and insulin sensitivity during obesityElise Dalmas, Amine Toubal, Fawaz Alzaid, et al.
Pageof 1